Nobivac Bb (live Bordetella bronchiseptica bacteria...) - QI06AE02
Updated on site: 09-Feb-2018
|Medication name:||Nobivac Bb|
|Substance:||live Bordetella bronchiseptica bacteria strain B-C2|
|Manufacturer:||Intervet International BV|
- What is Nobivac Bb?
- How does Nobivac Bb work?
- How has Nobivac Bb been studied?
- What benefit has Nobivac Bb shown during the studies?
- What is the risk associated with Nobivac Bb?
- What are the precautions for the person who gives the medicine or comes into contact with the animal?
- Why has Nobivac Bb been approved?
EPAR summary for the public
This document is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use. This document cannot replace a
What is Nobivac Bb?
Nobivac Bb is a vaccine that contains a live bacterium Bordetella bronchiseptica strain
What is Nobivac Bb used for?
Nobivac Bb is used to vaccinate cats aged one month or older against the disease (a
Cats are vaccinated by giving a
How does Nobivac Bb work?
Nobivac Bb is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against diseases. Nobivac Bb contains a type of live B. bronchiseptica called strain
How has Nobivac Bb been studied?
The effectiveness of Nobivac Bb was investigated in three main studies involving cats of various breeds. The cats were vaccinated with Nobivac Bb before being challenged by being exposed to
- Equilis prequenza - Intervet International BV
- Equilis strepe - Intervet International BV
- Nobilis influenza h5n2 - Intervet International BV
- Nobivac l4 - Intervet International BV
- Porcilis pesti - Intervet International BV
Prescription drugs listed. Manufacturer: "Intervet International BV"
What benefit has Nobivac Bb shown during the studies?
The main studies showed that Nobivac Bb was effective in reducing the symptoms caused by
What is the risk associated with Nobivac Bb?
Occasional side effects include sneezing, coughing and a mild and temporary discharge from the eyes or nose. In animals that show more severe signs, treatment with an antibiotic may be necessary.
What are the precautions for the person who gives the medicine or comes into contact with the animal?
The vaccine may be administered by veterinarians only. In case of accidental administration to people seek medical advice immediately and show the Package Leaflet or label to the doctor. Although the risk for people with weak immune systems becoming infected with B. bronchiseptica is extremely low, it is advised that cats which are in close contact with such people are not vaccinated with Nobivac Bb, since they can shed the bacteria intermittently for up to a year after vaccination.
Why has Nobivac Bb been approved?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Nobivac Bb exceed the risks of its use. The
Other information about Nobivac Bb:
The European Commission granted a marketing authorisation valid throughout the European Union for Nobivac Bb to Intervet International B.V. on 10 September 2002. The marketing authorisation was renewed on 25 September 2007. Information on the prescription status of this product may be found on the label/outer package.
This summary was last updated on 25 September 2007.